Our colleague Dr. Karin Gillner recently had a feature article on brown fat treatment research published in Journal for Clinical Studies.
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Internationally renowned clinical microbiologist takes academic lead in Horizon 2020 funded validation of game-changing method for multiple antibiotic resistance evaluation 11 April 2018: Symcel – the company behind the revolutionary cell-based...
L-R: Dr Marta Veses Garcia, Pelle Friberg and Dr Karin Gillner Symcel – producers of the cell-based assay tool for real-time cell metabolism measurements, calScreener — is expanding to bring its patented technology to the clinical antimicrobial...
Symcel secures €3.6 million Horizon 2020 Phase II grant for clinical validation of customized antimicrobial susceptibility testing. Multi-resistant bacterial sepsis infections to be validated utilising Symcel’s sensitive screening technology Symcel:...
Symcel AB today announces the appointment of Jesper Ericsson as new Chief Executive Officer – succeeding Christer Wallin who is now retiring. 1 September 2017: Symcel has today announced that Jesper Ericsson has joined Symcel as Chief Executive...